Assignee
ALLERGAN HOLDINGS UNLIMITED COMPANY
IE·10 granted patents·3 pending applications·32 citations·filing 2016–2023
Top patents by PatentIndex Score
13 records- 0195US11160792B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Granted Nov 2, 2021·4 cites·28 claims
- 0295US11090291B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Granted Aug 17, 2021·5 cites·24 claims
- 0395US11007179B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2020·Granted May 18, 2021·5 cites·30 claims
- 0494US11229627B1Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Granted Jan 25, 2022·3 cites·30 claims
- 0594US10188632B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2017·Granted Jan 29, 2019·8 cites·15 claims
- 0693US11311516B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Granted Apr 26, 2022·2 cites·30 claims
- 0790US11484527B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Granted Nov 1, 2022·1 cites·6 claims
- 0887US9789125B2Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1H-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acidALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2016·Granted Oct 17, 2017·4 cites·40 claims
- 0972US12097187B2Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2023·Granted Sep 24, 2024·0 cites·6 claims
- 1051US2021251964A1Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acidALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2019·Application pending·0 cites
- 1151US2023118152A1Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acidALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2021·Application pending·0 cites
- 1250US2022016034A1Opioid receptor modulator dosage formulationsALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2020·Application pending·0 cites
- 1335US10472329B2Process for the preparation of intermediates useful in the synthesis of EluxadolineALLERGAN HOLDINGS UNLIMITED COMPANY·Filed 2016·Granted Nov 12, 2019·0 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when ALLERGAN HOLDINGS UNLIMITED COMPANY files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →